科研动态期刊摘要
[评论] 所有错配修复缺陷的晚期或复发性子宫内膜癌患者是否仍需要化疗?
The Lancet · 2026-11-13
摘要
约四分之一的晚期或复发性子宫内膜癌为错配修复缺陷(dMMR)。1 在卡铂联合紫杉醇的基础上加用PD-1或PD-L1抑制剂已改变了该亚组的一线治疗格局,RUBY1、NRG-GY0182、AtTEnd3和DUO-E4试验报告其dMMR人群中无进展生存的危险比(HR)为0·28–0·42,RUBY的4年随访提示部分患者可能获得治愈。5 然而,这些试验中的每一项都保留了化疗。
English
[Comment] Is chemotherapy still needed in all patients with mismatch repair-deficient advanced or recurrent endometrial cancer?
Around a quarter of advanced or recurrent endometrial carcinomas are mismatch repair deficient (dMMR).1 Addition of a PD-1 or PD-L1 inhibitor to carboplatin plus paclitaxel has transformed first-line treatment for this subgroup, with the RUBY,1 NRG-GY018,2 AtTEnd,3 and DUO-E4 trials reporting hazard ratios (HRs) for progression-free survival of 0·28–0·42 in their dMMR populations, and 4-year follow-up of RUBY suggests that some patients might be cured.5 However, every one of these trials retained chemotherapy.